Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has provided an update.
Cosmo Pharmaceuticals has confirmed its financial forecast for 2025 remains unchanged despite a recent CHMP statement on the marketing authorization application for Winlevi® in Europe. While disappointed, the company is confident in Winlevi®’s clinical potential and is preparing to request a re-examination, emphasizing its commitment to ensuring patient access in Europe.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a pharmaceutical company focused on revolutionizing healthcare through innovative products that address unmet needs. Operating in Healthtech/AI, Dermatology, Gastroenterology, and contract manufacturing and development, Cosmo collaborates with global partners like Medtronic and Sun Pharma. Founded in 1997 and headquartered in Dublin, the company employs around 330 people.
YTD Price Performance: -23.81%
Average Trading Volume: 544
Technical Sentiment Signal: Buy
Current Market Cap: CHF816.6M
For an in-depth examination of COPN stock, go to TipRanks’ Stock Analysis page.